According to a Form 4 filing with the Securities and Exchange Commission, Mr. Moulder made two separate purchases of Zenas ...

Connect Biopharma is rated a risky Buy, with high upside potential hinging on mid-2026 Phase 2 trial results for rademikibart ...

Financing led by Sofinnova Investments and co-led by Forbion and Novo HoldingsProceeds to advance lead immunology program COL-5671, a potential ...

ASCEND Phase 1/2 global clinical trial ongoing, evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor ...

Crescent Biopharma, Inc. (CBIO) on Wednesday reported a loss of $23.3 million in its first quarter. The Waltham, Massachusetts-based company said it had a loss of 70 cents per share. The results ...

Backed by Novo Holdings, Regeneron’s venture arm and several others, the biotech believes an oral drug licensed from ...

The trial will assess the tolerability, safety, pharmacodynamics, and pharmacokinetics of BW-50218 in participants.

With an IPO raise of $625 million, Kailera Therapeutics now holds the new record for the largest public market debut.

The average one-year price target for Cue Biopharma (NasdaqCM:CUE) has been revised to $122.40 / share. This is an increase ...

Gilead, AstraZeneca and Vertex have acquired more than just a therapeutic asset in recent deals. BioSpace takes a look at five recent transactions where the staff was the real centerpiece.

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

Fapon Biopharma, a clinical-stage biotech company innovating therapeutic antibodies and fusion proteins, is pleased to announce its participation in the AACR Annual Meeting 2026, taking place April 19 ...